FDA Fast-Tracks Psychedelic Drugs From Compass, Usona
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA grants priority review vouchers to three psychedelic drug developers for mental health treatments, accelerating their path to market
- Compass Pathways confirms it received a voucher for its psilocybin therapy targeting treatment-resistant depression
- Trump administration pushes expanded access to psychedelics as part of a broader policy shift, despite ongoing legal scrutiny over unrelated national security claims
Why it matters: Compass Pathways and Usona gain faster FDA pathways for psilocybin depression treatments, potentially cutting review time by 4 months — a win for investors and patients, but raises regulatory scrutiny over rapid approval of mind-altering drugs.
